{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:43:10Z","timestamp":1794577390733,"version":"4.9.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T00:00:00Z","timestamp":1593907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T00:00:00Z","timestamp":1593907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The transport of proteins across the nuclear membrane is a highly regulated process, essential for the cell function. This transport is actively mediated by members of the karyopherin family, termed importins, or exportins, depending on the direction of transport. These proteins play an active part in tumorigenesis, through aberrant localization of their cargoes, which include oncogenes, tumor-suppressor genes and mediators of key signal transduction pathways. Overexpression of importins and exportins is reported in many malignancies, with implications in cell growth and viability, differentiation, drug resistance, and tumor microenvironment. Given their broad significance across tumors and pathways, much effort is being put to develop specific inhibitors as a novel anticancer therapeutics. Already, selinexor, a specific inhibitor of exportin-1 (XPO1), is approved for clinical use. This review will focus on the role of importins and exportins in hematological malignancies. We will discuss current preclinical and clinical data on importins and exportins, and demonstrate how our growing understanding of their functions has identified new therapeutic targets.<\/jats:p>","DOI":"10.1038\/s41375-020-0958-y","type":"journal-article","created":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T12:02:31Z","timestamp":1593950551000},"page":"2875-2886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Targeting nuclear import and export in hematological malignancies"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-2167","authenticated-orcid":false,"given":"Boaz","family":"Nachmias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-3899","authenticated-orcid":false,"given":"Aaron D.","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,5]]},"reference":[{"key":"958_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ceb.2018.01.006","volume":"52","author":"T \u00c7a\u011fatay","year":"2018","unstructured":"\u00c7a\u011fatay T, Chook YM. Karyopherins in cancer. Curr Opin Cell Biol. 2018;52:30\u201342.","journal-title":"Curr Opin Cell Biol"},{"key":"958_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/IJAM.IJAM_26_17","volume":"3","author":"S Stawicki","year":"2017","unstructured":"Stawicki S, Steffen J. The nuclear pore complex: a comprehensive review of structure and function. Int J Acad Med. 2017;3:24.","journal-title":"Int J Acad Med"},{"key":"958_CR3","doi-asserted-by":"crossref","first-page":"962","DOI":"10.15252\/msb.20177608","volume":"13","author":"M-T Mackmull","year":"2017","unstructured":"Mackmull M-T, Klaus B, Heinze I, Chokkalingam M, Beyer A, Russell RB, et al. Landscape of nuclear transport receptor cargo specificity. Mol Syst Biol. 2017;13:962.","journal-title":"Mol Syst Biol"},{"key":"958_CR4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2183\/pjab.94.018","volume":"94","author":"M Oka","year":"2018","unstructured":"Oka M, Yoneda Y. Importin \u03b1: functions as a nuclear transport factor and beyond. Proc Jpn Acad Ser B Phys Biol Sci. 2018;94:259\u201374.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"958_CR5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5115\/acb.2017.50.2.77","volume":"50","author":"YH Kim","year":"2017","unstructured":"Kim YH, Han M-E, Oh S-O. The molecular mechanism for nuclear transport and its application. Anat Cell Biol. 2017;50:77\u201385.","journal-title":"Anat Cell Biol"},{"key":"958_CR6","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1074\/jbc.M008522200","volume":"276","author":"MR Hodel","year":"2001","unstructured":"Hodel MR, Corbett AH, Hodel AE. Dissection of a nuclear localization signal. J Biol Chem. 2001;276:1317\u201325.","journal-title":"J Biol Chem"},{"key":"958_CR7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cell.2006.05.049","volume":"126","author":"BJ Lee","year":"2006","unstructured":"Lee BJ, Cansizoglu AE, S\u00fcel KE, Louis TH, Zhang Z, Chook YM. Rules for nuclear localization sequence recognition by karyopherin beta 2. Cell. 2006;126:543\u201358.","journal-title":"Cell"},{"key":"958_CR8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","volume":"27","author":"HYJ Fung","year":"2014","unstructured":"Fung HYJ, Chook YM. Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol. 2014;27:52\u201361.","journal-title":"Semin Cancer Biol"},{"key":"958_CR9","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1038\/emboj.2011.287","volume":"30","author":"T G\u00fcttler","year":"2011","unstructured":"G\u00fcttler T, G\u00f6rlich D. Ran-dependent nuclear export mediators: a structural perspective. EMBO J. 2011;30:3457\u201374.","journal-title":"EMBO J"},{"key":"958_CR10","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/sigtrans.2016.10","volume":"1","author":"Q Sun","year":"2016","unstructured":"Sun Q, Chen X, Zhou Q, Burstein E, Yang S, Jia D. Inhibiting cancer cell hallmark features through nuclear export inhibition. Signal Transduct Target Ther. 2016;1:16010.","journal-title":"Signal Transduct Target Ther"},{"key":"958_CR11","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","volume":"27","author":"J Schmidt","year":"2013","unstructured":"Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, et al. Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 2013;27:2357\u201365.","journal-title":"Leukemia"},{"key":"958_CR12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/sci.2019.02.03","volume":"6","author":"AY Wang","year":"2019","unstructured":"Wang AY, Liu H. The past, present, and future of CRM1\/XPO1 inhibitors. Stem Cell Investig. 2019;6:6.","journal-title":"Stem Cell Investig"},{"key":"958_CR13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"Y-T Tai","year":"2014","unstructured":"Tai Y-T, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28:155\u201365.","journal-title":"Leukemia"},{"key":"958_CR14","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","volume":"121","author":"K Kojima","year":"2013","unstructured":"Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013;121:4166\u201374.","journal-title":"Blood"},{"key":"958_CR15","first-page":"5547","volume":"11","author":"B Luo","year":"2018","unstructured":"Luo B, Huang L, Gu Y, Li C, Lu H, Chen G, et al. Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses. Int J Clin Exp Pathol. 2018;11:5547\u201360.","journal-title":"Int J Clin Exp Pathol"},{"key":"958_CR16","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","volume":"120","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, et al. Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120:4621\u201334.","journal-title":"Blood"},{"key":"958_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.exphem.2012.09.002","volume":"41","author":"K Zhang","year":"2013","unstructured":"Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013;41:67\u201378.e4.","journal-title":"Exp Hematol"},{"key":"958_CR18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/cas.12430","volume":"105","author":"M Yoshimura","year":"2014","unstructured":"Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quint\u00e1s-Cardama A, McDonnell TJ, et al. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 2014;105:795\u2013801.","journal-title":"Cancer Sci"},{"key":"958_CR19","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2013-04-495374","volume":"122","author":"CJ Walker","year":"2013","unstructured":"Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, et al. Preclinical and clinical efficacy of XPO1\/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013;122:3034\u201344.","journal-title":"Blood"},{"key":"958_CR20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.molcel.2011.11.022","volume":"45","author":"L Golomb","year":"2012","unstructured":"Golomb L, Bublik DR, Wilder S, Nevo R, Kiss V, Grabusic K, et al. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell. 2012;45:222\u201332.","journal-title":"Mol Cell"},{"key":"958_CR21","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1182\/blood-2014-04-567636","volume":"124","author":"J Bond","year":"2014","unstructured":"Bond J, Bergon A, Durand A, Tigaud I, Thomas X, Asnafi V, et al. Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. Blood. 2014;124:3023\u20135.","journal-title":"Blood"},{"key":"958_CR22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ajh.24451","volume":"91","author":"F Jardin","year":"2016","unstructured":"Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, et al. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma: XPO1 Mutations in Primary Mediastinal B-Cell Lymphoma. Am J Hematol. 2016;91:923\u201330.","journal-title":"Am J Hematol"},{"key":"958_CR23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-017-0412-4","volume":"10","author":"V Camus","year":"2017","unstructured":"Camus V, Miloudi H, Taly A, Sola B, Jardin F. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol. 2017;10:47.","journal-title":"J Hematol Oncol"},{"key":"958_CR24","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","volume":"101","author":"V Camus","year":"2016","unstructured":"Camus V, Stamatoullas A, Mareschal S, Viailly P-J, Sarafan-Vasseur N, Bohers E, et al. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica. 2016;101:1094\u2013101.","journal-title":"Haematologica"},{"key":"958_CR25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/leu.2013.263","volume":"28","author":"S Jeromin","year":"2014","unstructured":"Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014;28:108\u201317.","journal-title":"Leukemia"},{"key":"958_CR26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2014.04.005","volume":"27","author":"WT Senapedis","year":"2014","unstructured":"Senapedis WT, Baloglu E, Landesman Y. Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol. 2014;27:74\u201386.","journal-title":"Semin Cancer Biol"},{"key":"958_CR27","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1046\/j.1432-1327.2001.02227.x","volume":"268","author":"S-H Liang","year":"2001","unstructured":"Liang S-H, Clarke MF. Regulation of p53 localization: subcellular localization of p53. Eur J Biochem. 2001;268:2779\u201383.","journal-title":"Eur J Biochem"},{"key":"958_CR28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.onc.1203262","volume":"19","author":"W Lu","year":"2000","unstructured":"Lu W, Pochampally R, Chen L, Traidej M, Wang Y, Chen J. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene. 2000;19:232\u201340.","journal-title":"Oncogene"},{"key":"958_CR29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.leukres.2014.10.003","volume":"39","author":"X Han","year":"2015","unstructured":"Han X, Wang J, Shen Y, Zhang N, Wang S, Yao J, et al. CRM1 as a new therapeutic target for non-Hodgkin lymphoma. Leuk Res. 2015;39:38\u201346.","journal-title":"Leuk Res"},{"key":"958_CR30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","volume":"18","author":"UH Gandhi","year":"2018","unstructured":"Gandhi UH, Senapedis W, Baloglu E, Unger TJ, Chari A, Vogl D, et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18:335\u201345.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"958_CR31","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","volume":"7","author":"T Kashyap","year":"2016","unstructured":"Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, et al. Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 2016;7:78883\u201395.","journal-title":"Oncotarget"},{"key":"958_CR32","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/jca.7080","volume":"4","author":"JG Turner","year":"2013","unstructured":"Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, et al. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J Cancer. 2013;4:614\u201325.","journal-title":"J Cancer"},{"key":"958_CR33","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood-2005-11-4745","volume":"107","author":"B Falini","year":"2006","unstructured":"Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107:4514\u201323.","journal-title":"Blood"},{"key":"958_CR34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","volume":"34","author":"L Brunetti","year":"2018","unstructured":"Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang Y-H, Ramabadran R, et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell. 2018;34:499\u2013512.e9.","journal-title":"Cancer Cell"},{"key":"958_CR35","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2012-04-423160","volume":"120","author":"P Ranganathan","year":"2012","unstructured":"Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120:1765\u201373.","journal-title":"Blood"},{"key":"958_CR36","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","volume":"17","author":"M Ming","year":"2018","unstructured":"Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, et al. XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of I\u03baB. Mol Cancer Ther. 2018;17:2564\u201374.","journal-title":"Mol Cancer Ther"},{"key":"958_CR37","doi-asserted-by":"crossref","first-page":"e0137210","DOI":"10.1371\/journal.pone.0137210","volume":"10","author":"Y Tabe","year":"2015","unstructured":"Tabe Y, Kojima K, Yamamoto S, Sekihara K, Matsushita H, Davis RE, et al. Ribosomal biogenesis and translational flux inhibition by the selective inhibitor of nuclear export (SINE) XPO1 antagonist KPT-185. PLoS ONE. 2015;10:e0137210.","journal-title":"PLoS ONE"},{"key":"958_CR38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cellsig.2018.02.016","volume":"46","author":"H Miloudi","year":"2018","unstructured":"Miloudi H, Leroy K, Jardin F, Sola B. STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma. Cell Signal. 2018;46:76\u201382.","journal-title":"Cell Signal"},{"key":"958_CR39","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0092-8674(00)80372-4","volume":"90","author":"U Kutay","year":"1997","unstructured":"Kutay U, Bischoff FR, Kostka S, Kraft R, G\u00f6rlich D. Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor. Cell. 1997;90:1061\u201371.","journal-title":"Cell"},{"key":"958_CR40","doi-asserted-by":"crossref","first-page":"13077","DOI":"10.1007\/s13277-016-5301-x","volume":"37","author":"M-C Jiang","year":"2016","unstructured":"Jiang M-C. CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy. Tumour Biol J Int Soc Oncodev Biol Med. 2016;37:13077\u201390.","journal-title":"Tumour Biol J Int Soc Oncodev Biol Med"},{"key":"958_CR41","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1073\/pnas.96.16.9112","volume":"96","author":"N Kudo","year":"1999","unstructured":"Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, et al. Leptomycin B inactivates CRM1\/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA. 1999;96:9112\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"958_CR42","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1073\/pnas.1217203110","volume":"110","author":"Q Sun","year":"2013","unstructured":"Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci USA. 2013;110:1303\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"958_CR43","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","volume":"74","author":"ES Newlands","year":"1996","unstructured":"Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996;74:648\u20139.","journal-title":"Br J Cancer"},{"key":"958_CR44","first-page":"538","volume":"4","author":"A Dickmanns","year":"2015","unstructured":"Dickmanns A, Monecke T, Ficner R. Structural basis of targeting the exportin CRM1 in. Cancer Cells. 2015;4:538\u201368.","journal-title":"Cancer Cells"},{"key":"958_CR45","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.18632\/oncotarget.2174","volume":"5","author":"J Mendonca","year":"2014","unstructured":"Mendonca J, Sharma A, Kim H-S, Hammers H, Meeker A, De Marzo A, et al. Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget. 2014;5:6102\u201312.","journal-title":"Oncotarget"},{"key":"958_CR46","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0188-6","volume":"9","author":"JP Abeykoon","year":"2019","unstructured":"Abeykoon JP, Paludo J, Nowakowski KE, Stenson MJ, King RL, Wellik LE, et al. The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells. Blood Cancer J. 2019;9:24.","journal-title":"Blood Cancer J"},{"key":"958_CR47","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","volume":"129","author":"J Kuruvilla","year":"2017","unstructured":"Kuruvilla J, Savona M, Baz R, Mau-Sorensen PM, Gabrail N, Garzon R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017;129:3175\u201383.","journal-title":"Blood"},{"key":"958_CR48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","volume":"547","author":"LI Shlush","year":"2017","unstructured":"Shlush LI, Mitchell A, Heisler L, Abelson S, Ng SWK, Trotman-Grant A, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547:104\u20138.","journal-title":"Nature"},{"key":"958_CR49","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/gcc.22805","volume":"58","author":"M Chopra","year":"2019","unstructured":"Chopra M, Bohlander SK. The cell of origin and the leukemia stem cell in acute myeloid leukemia. Genes Chromosom Cancer. 2019;58:850\u20138.","journal-title":"Genes Chromosom Cancer"},{"key":"958_CR50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/leu.2015.194","volume":"30","author":"J Etchin","year":"2016","unstructured":"Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, et al. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2016;30:190\u20139.","journal-title":"Leukemia"},{"key":"958_CR51","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-16-1580","volume":"23","author":"T Vercruysse","year":"2017","unstructured":"Vercruysse T, De Bie J, Neggers JE, Jacquemyn M, Vanstreels E, Schmid-Burgk JL, et al. The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia. Clin Cancer Res J Am Assoc Cancer Res. 2017;23:2528\u201341.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"958_CR52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/leu.2016.145","volume":"31","author":"J Etchin","year":"2017","unstructured":"Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. 2017;31:143\u201350.","journal-title":"Leukemia"},{"key":"958_CR53","doi-asserted-by":"crossref","first-page":"78896","DOI":"10.18632\/oncotarget.12969","volume":"7","author":"JG Turner","year":"2016","unstructured":"Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, et al. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016;7:78896\u2013909.","journal-title":"Oncotarget"},{"key":"958_CR54","doi-asserted-by":"crossref","first-page":"25529","DOI":"10.18632\/oncotarget.25368","volume":"9","author":"C Argueta","year":"2018","unstructured":"Argueta C, Kashyap T, Klebanov B, Unger TJ, Guo C, Harrington S, et al. Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death. Oncotarget. 2018;9:25529\u201344.","journal-title":"Oncotarget"},{"key":"958_CR55","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","volume":"22","author":"P Ranganathan","year":"2016","unstructured":"Ranganathan P, Kashyap T, Yu X, Meng X, Lai T-H, McNeil B, et al. XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase II\u03b1 to the nucleus. Clin Cancer Res J Am Assoc Cancer Res. 2016;22:6142\u201352.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"958_CR56","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood-2014-10-607648","volume":"125","author":"P Ranganathan","year":"2015","unstructured":"Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, et al. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood. 2015;125:2689\u201392.","journal-title":"Blood"},{"key":"958_CR57","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","volume":"22","author":"X Niu","year":"2016","unstructured":"Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, et al. Binding of released bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res J Am Assoc Cancer Res. 2016;22:4440\u201351.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"958_CR58","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1111\/jcmm.13886","volume":"22","author":"DA Luedtke","year":"2018","unstructured":"Luedtke DA, Su Y, Liu S, Edwards H, Wang Y, Lin H, et al. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1. J Cell Mol Med. 2018;22:6099\u2013111.","journal-title":"J Cell Mol Med"},{"key":"958_CR59","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3324\/haematol.2017.185082","volume":"103","author":"W Zhang","year":"2018","unstructured":"Zhang W, Ly C, Ishizawa J, Mu H, Ruvolo V, Shacham S, et al. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica. 2018;103:1642\u201353.","journal-title":"Haematologica"},{"key":"958_CR60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR\u2013ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172\u201383.","journal-title":"Nat Rev Cancer"},{"key":"958_CR61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/84683","volume":"7","author":"P Vigneri","year":"2001","unstructured":"Vigneri P, Wang JYJ. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR\u2013ABL tyrosine kinase. Nat Med. 2001;7:228\u201334.","journal-title":"Nat Med"},{"key":"958_CR62","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2014-08-588855","volume":"125","author":"JS Khorashad","year":"2015","unstructured":"Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, et al. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood. 2015;125:1772\u201381.","journal-title":"Blood"},{"key":"958_CR63","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/leu.2014.9","volume":"28","author":"Y Zhong","year":"2014","unstructured":"Zhong Y, El-Gamal D, Dubovsky JA, Beckwith KA, Harrington BK, Williams KE, et al. Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia. 2014;28:1158\u201363.","journal-title":"Leukemia"},{"key":"958_CR64","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","volume":"125","author":"ZA Hing","year":"2015","unstructured":"Hing ZA, Mantel R, Beckwith KA, Guinn D, Williams E, Smith LL, et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood. 2015;125:3128\u201332.","journal-title":"Blood"},{"key":"958_CR65","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","volume":"131","author":"C Chen","year":"2018","unstructured":"Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister CC, Gabrail N, et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood. 2018;131:855\u201363.","journal-title":"Blood"},{"key":"958_CR66","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral Selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727\u201338.","journal-title":"N Engl J Med"},{"key":"958_CR67","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","volume":"36","author":"DT Vogl","year":"2018","unstructured":"Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol J Am Soc Clin Oncol. 2018;36:859\u201366.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"958_CR68","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","volume":"132","author":"NJ Bahlis","year":"2018","unstructured":"Bahlis NJ, Sutherland H, White D, Sebag M, Lentzsch S, Kotb R, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132:2546\u201354.","journal-title":"Blood"},{"key":"958_CR69","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjh.15969","volume":"186","author":"AJ Jakubowiak","year":"2019","unstructured":"Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, et al. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed\/refractory multiple myeloma. Br J Haematol. 2019;186:549\u201360.","journal-title":"Br J Haematol"},{"key":"958_CR70","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","volume":"34","author":"AR Abdul Razak","year":"2016","unstructured":"Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, et al. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol J Am Soc Clin Oncol. 2016;34:4142\u201350.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"958_CR71","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2016-11-752840","volume":"130","author":"KR Machlus","year":"2017","unstructured":"Machlus KR, Wu SK, Vijey P, Soussou TS, Liu Z-J, Shacham E, et al. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017;130:1132\u201343.","journal-title":"Blood"},{"key":"958_CR72","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","volume":"129","author":"R Garzon","year":"2017","unstructured":"Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129:3165\u201374.","journal-title":"Blood"},{"key":"958_CR73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10428194.2019.1665664","volume":"61","author":"B Bhatnagar","year":"2020","unstructured":"Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, et al. Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leuk Lymphoma. 2020;61:387\u201396.","journal-title":"Leuk Lymphoma"},{"key":"958_CR74","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-017-0550-8","volume":"11","author":"AY Wang","year":"2018","unstructured":"Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, et al. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol OncolJ Hematol Oncol. 2018;11:4.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"958_CR75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/1078-0432.CCR-19-2169","volume":"26","author":"K Sweet","year":"2020","unstructured":"Sweet K, Komrokji R, Padron E, Cubitt CL, Turner JG, Zhou J, et al. Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia. Clin Cancer Res. 2020;26:54\u201360.","journal-title":"Clin Cancer Res"},{"key":"958_CR76","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.3324\/haematol.2017.181636","volume":"103","author":"S Bobillo","year":"2018","unstructured":"Bobillo S, Abrisqueta P, Carpio C, Raheja P, Castellv\u00ed J, Crespo M, et al. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. Haematologica. 2018;103:e92\u2013e93.","journal-title":"Haematologica"},{"key":"958_CR77","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00432-015-2057-4","volume":"142","author":"S He","year":"2016","unstructured":"He S, Miao X, Wu Y, Zhu X, Miao X, Yin H, et al. Upregulation of nuclear transporter, Kpn\u03b21, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2016;142:561\u201372.","journal-title":"J Cancer Res Clin Oncol"},{"key":"958_CR78","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.cellsig.2015.01.013","volume":"27","author":"W Yan","year":"2015","unstructured":"Yan W, Li R, He J, Du J, Hou J. Importin \u03b21 mediates nuclear factor-\u03baB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis. Cell Signal. 2015;27:851\u20139.","journal-title":"Cell Signal"},{"key":"958_CR79","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2019-122284","volume":"134","author":"B Nachmias","year":"2019","unstructured":"Nachmias B, Voisin V, Hurren R, Wang X, Maclean N, Xu GW, et al. IPO11 is upregulated in relapsed AML and supports survival of leukemic stem cells. Blood. 2019;134:2530\u20132530.","journal-title":"Blood"},{"key":"958_CR80","doi-asserted-by":"crossref","first-page":"117140","DOI":"10.1016\/j.lfs.2019.117140","volume":"241","author":"Y Han","year":"2020","unstructured":"Han Y, Wang X. The emerging roles of KPNA2 in cancer. Life Sci. 2020;241:117140.","journal-title":"Life Sci"},{"key":"958_CR81","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","volume":"2","author":"Y Xia","year":"2014","unstructured":"Xia Y, Shen S, Verma IM. NF-\u03baB, an active player in human cancers. Cancer Immunol Res. 2014;2:823\u201330.","journal-title":"Cancer Immunol Res"},{"key":"958_CR82","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3324\/haematol.11199","volume":"92","author":"D Cilloni","year":"2007","unstructured":"Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G. Nuclear factor B as a target for new drug development in myeloid malignancies. Haematologica. 2007;92:1224\u20139.","journal-title":"Haematologica"},{"key":"958_CR83","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00432-015-2057-4","volume":"142","author":"S He","year":"2016","unstructured":"He S, Miao X, Wu Y, Zhu X, Miao X, Yin H, et al. Upregulation of nuclear transporter, Kpn\u03b21, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2016;142:561\u201372.","journal-title":"J Cancer Res Clin Oncol"},{"key":"958_CR84","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","volume":"32","author":"W Vainchenker","year":"2013","unstructured":"Vainchenker W, Constantinescu SN. JAK\/STAT signaling in hematological malignancies. Oncogene. 2013;32:2601\u201313.","journal-title":"Oncogene"},{"key":"958_CR85","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/1541-7786.MCR-16-0344","volume":"15","author":"F Zhu","year":"2017","unstructured":"Zhu F, Hwang B, Miyamoto S, Rui L. Nuclear import of JAK1 is mediated by a classical NLS and is required for survival of diffuse large B-cell lymphoma. Mol Cancer Res. 2017;15:348\u201357.","journal-title":"Mol Cancer Res"},{"key":"958_CR86","doi-asserted-by":"publisher","unstructured":"Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012; 4. https:\/\/doi.org\/10.1101\/cshperspect.a008052.","DOI":"10.1101\/cshperspect.a008052"},{"key":"958_CR87","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/bs.pmbts.2017.11.002","volume":"153","author":"S Grainger","year":"2018","unstructured":"Grainger S, Traver D, Willert K. Wnt signaling in hematological malignancies. Prog Mol Biol Transl Sci. 2018;153:321\u201341.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"958_CR88","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.bbrc.2016.08.093","volume":"478","author":"T Lu","year":"2016","unstructured":"Lu T, Bao Z, Wang Y, Yang L, Lu B, Yan K, et al. Karyopherin\u03b21 regulates proliferation of human glioma cells via Wnt\/\u03b2-catenin pathway. Biochem Biophys Res Commun. 2016;478:1189\u201397.","journal-title":"Biochem Biophys Res Commun"},{"key":"958_CR89","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biocel.2016.06.024","volume":"78","author":"DK Mohammad","year":"2016","unstructured":"Mohammad DK, Nore BF, Gustafsson MO, Mohamed AJ, Smith CIE. Protein kinase B (AKT) regulates SYK activity and shuttling through 14-3-3 and importin 7. Int J Biochem Cell Biol. 2016;78:63\u201374.","journal-title":"Int J Biochem Cell Biol"},{"key":"958_CR90","doi-asserted-by":"crossref","first-page":"109567","DOI":"10.1016\/j.cellsig.2020.109567","volume":"69","author":"J Ye","year":"2020","unstructured":"Ye J, Zhong L, Xiong L, Li J, Yu L, Dan W, et al. Nuclear import of NLS- RAR\u03b1 is mediated by importin \u03b1\/\u03b2. Cell Signal. 2020;69:109567.","journal-title":"Cell Signal"},{"key":"958_CR91","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7150\/ijms.6518","volume":"11","author":"X-X Hu","year":"2014","unstructured":"Hu X-X, Zhong L, Zhang X, Gao Y-M, Liu B-Z. NLS-RAR\u03b1 promotes proliferation and inhibits differentiation in HL-60 cells. Int J Med Sci. 2014;11:247\u201354.","journal-title":"Int J Med Sci"},{"key":"958_CR92","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1038\/sj.onc.1203689","volume":"19","author":"Y Odaka","year":"2000","unstructured":"Odaka Y, Mally A, Elliott LT, Meyers S. Nuclear import and subnuclear localization of the proto-oncoprotein ETO (MTG8). Oncogene. 2000;19:3584\u201397.","journal-title":"Oncogene"},{"key":"958_CR93","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.2147\/OTT.S210048","volume":"12","author":"T Wang","year":"2019","unstructured":"Wang T, Huang Z, Huang N, Peng Y, Gao M, Wang X, et al. Inhibition of KPNB1 inhibits proliferation and promotes apoptosis of chronic myeloid leukemia cells through regulation of E2F1. OncoTargets Ther. 2019;12:10455\u201367.","journal-title":"OncoTargets Ther"},{"key":"958_CR94","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2009-02-205153","volume":"114","author":"S Assouline","year":"2009","unstructured":"Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 2009;114:257\u201360.","journal-title":"Blood"},{"key":"958_CR95","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1073\/pnas.1524291113","volume":"113","author":"L Volpon","year":"2016","unstructured":"Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, et al. Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E. Proc Natl Acad Sci USA. 2016;113:5263\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"958_CR96","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/humu.23157","volume":"38","author":"T Heikkinen","year":"2017","unstructured":"Heikkinen T, K\u00e4mpj\u00e4rvi K, Keskitalo S, von Nandelstadh P, Liu X, Rantanen V, et al. Somatic MED12 nonsense mutation escapes mRNA decay and reveals a motif required for nuclear entry. Hum Mutat. 2017;38:269\u201374.","journal-title":"Hum Mutat"},{"key":"958_CR97","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/gcc.20121","volume":"42","author":"MJ Edick","year":"2005","unstructured":"Edick MJ, Cheng C, Yang W, Cheok M, Wilkinson MR, Pei D, et al. Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosom Cancer. 2005;42:107\u201316.","journal-title":"Genes Chromosom Cancer"},{"key":"958_CR98","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1021\/cb2000296","volume":"6","author":"JF Soderholm","year":"2011","unstructured":"Soderholm JF, Bird SL, Kalab P, Sampathkumar Y, Hasegawa K, Uehara-Bingen M, et al. Importazole, a small molecule inhibitor of the transport receptor importin-\u03b2. ACS Chem Biol. 2011;6:700\u20138.","journal-title":"ACS Chem Biol"},{"key":"958_CR99","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1038\/s41388-019-0745-2","volume":"38","author":"J Yang","year":"2019","unstructured":"Yang J, Guo Y, Lu C, Zhang R, Wang Y, Luo L, et al. Inhibition of karyopherin beta 1 suppresses prostate cancer growth. Oncogene. 2019;38:4700\u201314.","journal-title":"Oncogene"},{"key":"958_CR100","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1158\/1535-7163.MCT-15-0052","volume":"15","author":"PJ van der Watt","year":"2016","unstructured":"van der Watt PJ, Chi A, Stelma T, Stowell C, Strydom E, Carden S, et al. Targeting the nuclear import receptor Kpn\u03b21 as an anticancer therapeutic. Mol Cancer Ther. 2016;15:560\u201373.","journal-title":"Mol Cancer Ther"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0958-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0958-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0958-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:41:32Z","timestamp":1684618892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0958-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,5]]},"references-count":100,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["958"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0958-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,5]]},"assertion":[{"value":"7 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"ADS has received honorarium from Novartis, Jazz, and Otsuka Pharmaceuticals and research support from Medivir AB and Takeda. ADS is named as an inventor on a patent application related to the use of DNT cells in AML. ADS owns stock in AbbVie Pharmaceuticals ADS hold the Ronald N. Buick Chair in Oncology Research. BN\u2014no COI to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}